He Gilead’s remdesivir failed a COVID-19 trial carried out by the World Health Organization. According to the report, the drug did not have a substantial effect on the survival chances of coronavirus patients, nor did the hospitalization time decrease.
The antiviral drug, one of the first to be used as a treatment for COVID-19, was one of the drugs that was recently used to treat coronavirus infection of the president of the United States, Donald Trump.
The WHO trial, called Solidarity, evaluated the effects of four possible drug regimens in 11,266 hospitalized patients. The drugs included in the research were:
- A lopinavir anti-HIV combination drug
- Ritonavir and interferon
The hydroxychloroquine was discontinued in June after it will prove ineffectiveBut the other trials continued in more than 500 hospitals and 30 countries, WHO chief scientist Soumya Swaminathan said at an event on Wednesday.
The study found that none of the treatments “substantially affected mortality” The reduced the need to ventilate patients with COVID-19.
Earlier this month Gilead said remdesivir shortened recovery time from COVID-19 in five days compared to patients taking placebo in a study of 1,062 patients. The results were published in the New England Journal of Medicine.
Remdesivir conflict: Gilead insists it does work against COVID-19
Gallery: What are the symptoms of la influenza and los of Covid-19? (Fifth Estate)
Gilead, which obtained the data from Solidarity 10 days ago, disputed the findings, saying they appear “inconsistent compared to the strongest evidence from multiple randomized controlled studies published in peer-reviewed journals that validate the clinical benefit of remdesivir“.
However, WHO scientists immediately responded to the controversy:
“It is a reliable result, do not let anyone tell you otherwise, because they will try.”
Richard Peto, an independent statistician hired by WHO to analyze the results of the Solidarity trial.
The WHO refrained from making a recommendation on how countries should implement remdesivir, saying that guidance would arrive in two to three weeks after a review of the study data.
MORE NEWS -:
Why is it good news that the most aggressive viruses are the least contagious (and what about the coronavirus) (BBC Mundo)
Click to see the full video